MD | DC | VA
Our Goal: To become a Top 3 BioHealth Hub by 2023.
Driving Innovation and Entrepreneurship
- World–renowned research institutions and universities
- Influential policymakers and advocacy groups pioneering new health strategies
- World–leading infectious disease research and vaccine development
- Fastest growing region for healthcare companies in the U.S.
- Rated #1 in the nation for science and engineering talent
- Mission control for the National Cancer Moonshot Initiative
Founding Partners
APEIRON to utilize MaxCyte’s ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials VIENNA, AUSTRIA and GAITHERSBURG, MD, July 8, 2020 APEIRON Biologics…
Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military…
• Collaboration combines innovative plant-based and adjuvant technologies to develop and produce a COVID-19 candidate vaccine. • Phase 1 clinical testing scheduled to begin mid-July • Collaboration to explore vaccine…
Emergent will provide contract development and manufacturing services beginning in 2021 to produce drug substance at large scale for commercial manufacturing with first two years valued at approximately $480 million…
GAITHERSBURG, Md., July 02, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Frank Czworka as Senior Vice President, Global Sales,…
$5.1M Series A Funding Led by Ajax Health Will Be Used to Develop First-in-Class Product Designed with Three-Dimensional, Independent Steerability to Deliver Reliable Access June 30, 2020 08:00 AM Eastern…